Legend Biotech Posts Strong Q2 2026 Growth on CARVYKTI Surge
Event summary
- CARVYKTI net trade sales increased 50% YoY to $657 million in Q2 2026.
- LB2501 achieved 100% ORR and 83.3% CR in relapsed/refractory B-cell NHL trials.
- Company raised $212 million through public offering of ADS, boosting cash position to $965 million.
- Net income swung to $33.2 million from a loss of $125.4 million YoY.
The big picture
Legend Biotech's Q2 2026 results highlight the accelerating adoption of CARVYKTI in multiple myeloma, while early-stage pipeline successes suggest diversification potential. The company's strategic focus on expanding patient access and strengthening its balance sheet positions it to compete with larger cell therapy players like Kite Pharma and Bristol Myers Squibb.
What we're watching
- Commercial Momentum
- Whether Legend Biotech can sustain CARVYKTI's 50% YoY growth amid expanding global access.
- Pipeline Progress
- The pace at which LB2501 and LB2102 advance through clinical trials could diversify revenue streams.
- Financial Discipline
- How the company manages its $965 million cash position to achieve profitability by 2026.
Related topics